Jacob Berchuck

🚀 Excited to share that I’ve joined @EmoryMedicine & @WinshipAtEmory to launch The Berchuck Lab. Our research is focused on using liquid biopsy to improve outcomes for people living with cancer. We’re hiring for several key roles! Learn more & apply: theberchucklab.org

🚨 Check out our new post in @ASCO Daily News 🔎Exploring emerging paradigms transforming metastatic hormone-sensitive prostate cancer care - from novel systemic therapies to personalized strategies. A shift in practice is underway!! @jberchuck @EHeath4100 & Dr. Brad Carthon…

🚨 Excited to share our manuscript in @Nature_NPJ highlighting the expanding role of liquid biopsy to detect clinically actionable non-genomic mechanisms of therapeutic resistance. Led by @KarlSemaan @RashadNawfal with collaborators @SylvanBacaLab @DrChoueiri #MattFreedman.

Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in #mCRPC. Presentation by @jberchuck @EmoryMedicine. #ASCO25 written coverage by @RKSayyid @USC > bit.ly/43Qj5uG @ASCO

Winship medical oncologist Jacob E. Berchuck, MD recently spoke with @targetedonc on how a new epigenomic platform may influence the accessibility of prostate-specific membrane antigen-based therapies. ➡️ brnw.ch/21wPMdh

Data presented at #ISLB24 suggest that epigenomic cfDNA may accurately assess PSMA expression and predict Lu-PSMA response in mCRPC. @jberchuck @emory_urology #pcsm urologytimes.com/view/epigenomi…

Honored to be awarded best poster at the @isliquidbiopsy #ISLB24 Annual Congress for our work using a novel epigenomic liquid biopsy platform to detect PSMA expression and predict Pluvicto response in mCRPC. CC: fantastic collaborators @PrafulRavi1 @HJacene @Precede_Bio

Thank you @isliquidbiopsy for the opportunity to speak on the potential of liquid biopsies for early cancer detection at #ISLB24. Congrats to @ChristianRolfo and co for organizing a fantastic conference!

Fantastic @CCR_AACR Translations piece from @jberchuck & colleagues on our recent @CCR_AACR paper uncovering a stemness signature enriched in cfDNA in lethal AR-altered prostate cancer patients. @pradeep198212 @MayoRadOnc @MayoCancerCare @MayoClinic aacrjournals.org/clincancerres/…

📊 Revolutionary approach: Analyzing cell-free DNA to track PSMA expression in real-time. Dr. Jake Berchuck (@jberchuck) discusses how this could transform treatment decisions in prostate cancer. Watch the complete discussion on @urotoday: tinyurl.com/e6aj8b38

Novel epigenomic liquid biopsy detects PSMA expression in #ProstateCancer. @jberchuck @WinshipAtEmory and Oliver Sartor, MD @MayoClinic dive into this cutting-edge epigenomic liquid biopsy platform that uses cell-free DNA to infer PSMA expression. This novel assay shows a strong…

Challenging prostate cancer subtypes like liver metastases and neuroendocrine #prostatecancer may ultimately benefit from more precise treatment approaches, thanks to innovative liquid biopsy technology. @sartor_oliver & @jberchuck discuss on @urotday- bit.ly/4ewKx4I

WATCH: Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at #ESMO24. @jberchuck @EmoryMedicine @WinshipAtEmory targetedonc.com/view/epigenomi…

I can’t think of anyone more deserving of this recognition. Matt Freedman is an extraordinary scientist, mentor, and colleague who has made equally immense and indelible impacts on the field of cancer epigenetics / liquid biopsy and the careers and future success of his mentees.